Latest Market Entry News

Sparc Technologies reveals up to 60% corrosion reduction in graphene-enhanced water-based epoxy coatings, reinforcing its leadership in sustainable protective coatings innovation.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.

Perenti Limited has delivered record financial results for FY25, driven by strong operational performance and strategic contract wins, including its first underground mining contract in the USA. The company also improved its safety record and advanced key sustainability initiatives.

Objective Corporation reports robust FY2025 results with strong recurring revenue growth and deepening AI integration, setting ambitious targets for FY2026.

RooLife Group Ltd (ASX, RLG) has launched its proprietary RLG Coffee brand in China, tapping into a rapidly expanding market with early sales exceeding $110,000 in the first month. Strategic partnerships and a recent supply deal position RLG for broader growth in the country’s evolving consumer landscape.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Xamble Group Limited is accelerating its transformation into Southeast Asia’s premier influencer marketing platform, reporting strong H1 revenue growth and launching a strategic rights issue to fund expansion and technology upgrades.